---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-24-000015"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T01:21:27.861965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback

## Summary
- GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).
- Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).
- Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.
- Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.
- 2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged.

## SEC filing metadata
- accession: 0001804220-24-000015
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/regn-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-24-000015
- JSON: https://secwatch.observer/filing/0001804220-24-000015.json
- Plain text: https://secwatch.observer/filing/0001804220-24-000015.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: reported results
  source text: On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.